Aevitas Wealth Management, Inc. Eli Lilly & CO Transaction History

Aevitas Wealth Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 26, 2019	SELL	$110.79 - $129.32 $50,409 - $58,840	-455 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$105.9 - $118.64 $10,484 - $11,745	-99 Reduced 17.87%	455 $53,000
Q3 2018 Nov 14, 2018	BUY	$85.86 - $107.31 $85 - $107	1 Added 0.18%	554 $59,000
Q2 2018 Aug 10, 2018	BUY	$75.7 - $86.88 $75 - $86	1 Added 0.18%	553 $47,000
Q1 2018 May 15, 2018	BUY	$74.21 - $87.6 $7,495 - $8,847	101 Added 22.39%	552 $43,000
Q4 2017 Feb 13, 2018	BUY	$81.94 - $87.89 $36,954 - $39,638	451	451 $38,000

3,912

765M

6.35M

7.95M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $788B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Aevitas Wealth Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Aevitas Wealth Management, Inc. with notifications on news.